MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON, Canada.
Athabasca University, Athabasca, AB, Canada.
BMC Cardiovasc Disord. 2021 Mar 25;21(1):151. doi: 10.1186/s12872-021-01955-1.
National essential medicines lists are used to guide medicine reimbursement and public sector medicine procurement for many countries therefore medicine listings may impact health outcomes.
Countries' national essential medicines lists were scored on whether they listed proven medicines for ischemic heart disease, cerebrovascular disease and hypertensive heart disease. In this cross sectional study linear regression was used to measure the association between countries' medicine coverage scores and healthcare access and quality scores.
There was an association between healthcare access and quality scores and health expenditure for ischemic heart disease (p ≤ 0.001), cerebrovascular disease (p ≤ 0.001) and hypertensive heart disease (p ≤ 0.001). However, there was no association between medicine coverage scores and healthcare access and quality scores for ischemic heart disease (p = 0.252), cerebrovascular disease (p = 0.194) and hypertensive heart disease (p = 0.209) when country characteristics were accounted for.
Listing more medicines on national essential medicines lists may only be one factor in reducing mortality from cardiovascular disease and improving healthcare access and quality scores.
许多国家都使用国家基本药物清单来指导药品报销和公共部门药品采购，因此药品清单可能会影响健康结果。
本横断面研究对各国的国家基本药物清单进行了评分，以评估其是否列出了缺血性心脏病、脑血管疾病和高血压性心脏病的已证实药物。采用线性回归来衡量各国药物覆盖评分与医疗保健可及性和质量评分之间的关联。
在缺血性心脏病（p≤0.001）、脑血管疾病（p≤0.001）和高血压性心脏病（p≤0.001）方面，医疗保健可及性和质量评分与卫生支出之间存在关联。然而，当考虑到国家特征时，药物覆盖评分与缺血性心脏病（p=0.252）、脑血管疾病（p=0.194）和高血压性心脏病（p=0.209）的医疗保健可及性和质量评分之间没有关联。
在国家基本药物清单中列出更多的药物可能只是降低心血管疾病死亡率和改善医疗保健可及性和质量评分的一个因素。
